By Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

Most people know endorphins as the "feel-good" chemicals behind a runner's high. But endorphins are far more than a post-workout reward signal—they are potent endogenous opioid peptides that modulate pain, stress resilience, immune function, mood, and social bonding. Understanding how your body produces, processes, and regulates these molecules opens the door to practical strategies for optimizing what I call "endorphin tone"—the baseline level of endorphin signaling that shapes how you experience pain, stress, and well-being on a daily basis.

This article walks through the biochemistry of endorphin production, the physiological systems that regulate it, and the evidence-informed clinical levers we can use to support healthy endorphin signaling—without resorting to exogenous opioids.

What Are Endorphins, and How Are They Different from Other Endogenous Opioids?

Endorphins belong to a broader family of endogenous opioid peptides that includes enkephalins, dynorphins, endomorphins, and nociceptin. Each family is derived from a different precursor protein, binds preferentially to different opioid receptor subtypes, and plays distinct physiological roles. When we talk about "endorphins" in the clinical sense, we are usually referring to β-endorphin, a 31-amino-acid peptide that is the most potent and best-studied member of the endorphin family.

What makes β-endorphin clinically significant is its high affinity for the μ-opioid receptor (MOR)—the same receptor targeted by morphine and other pharmaceutical opioids—along with some activity at the δ-opioid receptor. This receptor profile underlies β-endorphin's powerful analgesic, mood-elevating, and immune-modulating properties.

How Your Body Makes β-Endorphin: The POMC Pathway

β-Endorphin is not synthesized directly. It is cleaved from a larger precursor protein called proopiomelanocortin (POMC), which is encoded by the POMC gene. POMC is a remarkable molecule—it is the shared precursor for several biologically active peptides, including ACTH (the hormone that drives cortisol production), α-MSH (involved in pigmentation and appetite regulation), and β-endorphin itself. This shared origin means that the systems governing stress, pain, inflammation, pigmentation, and appetite are biochemically intertwined at the level of a single gene product.

The Production Sequence

The journey from gene to active peptide follows a carefully orchestrated pathway:

Transcription and translation. The POMC gene is transcribed into mRNA, which is then translated on the rough endoplasmic reticulum into a large precursor called prepro-POMC. A signal peptide is cleaved to produce pro-POMC, which is routed through the Golgi apparatus into secretory granules.

Proteolytic processing. Inside those secretory granules, specialized enzymes called prohormone convertases—primarily PC1/3 and PC2—cleave pro-POMC at specific sites. The intermediate product β-lipotropin (β-LPH) is further cleaved to yield β-endorphin. Additional trimming by carboxypeptidase E (CPE) can generate shorter variants like α-endorphin and γ-endorphin, each with somewhat different biological activities.

Molecular requirements. This entire process depends on intact DNA transcription machinery, a full complement of amino acids (particularly tyrosine, glycine, and phenylalanine, which form the critical N-terminal Tyr-Gly-Gly-Phe motif shared by all opioid peptides), ATP/GTP for energy, and the convertase enzymes themselves. Deficiencies at any step can impair endorphin production.

Where Does This Happen?

POMC-expressing cells are found in several locations throughout the body, and the peptide products they generate differ based on which convertases are expressed in each tissue:

Pituitary corticotrophs primarily produce ACTH and β-endorphin, releasing them into the bloodstream as part of the HPA stress response.

Hypothalamic arcuate neurons process POMC more extensively, generating α-MSH (important for appetite and energy balance) along with β-endorphin, which acts locally in the central nervous system.

Skin keratinocytes produce β-endorphin in response to UV and blue-light exposure—a fascinating peripheral pathway with implications for phototherapy and even sun-seeking behavior.

Immune cells (particularly activated lymphocytes and macrophages) produce β-endorphin at sites of inflammation, contributing to local pain modulation and immune regulation.

This tissue-specific processing is an important concept: the same gene produces different functional outputs depending on where it is expressed. It also means that strategies to support endorphin production may work through different mechanisms in different tissues.

What Endorphins Do: Beyond Pain Relief

While analgesia is the best-known function of β-endorphin, its physiological roles are broader than most people appreciate.

Pain modulation and stress buffering. β-Endorphin is released during acute physical and psychological stress, providing a natural analgesic and anxiolytic buffer. This is the mechanism behind phenomena like stress-induced analgesia—the temporary inability to feel pain during a crisis.

Mood and reward. Endorphin signaling contributes to the subjective experience of pleasure, reward, and well-being. It plays a role in the neurochemistry of social bonding, laughter, music appreciation, and the "afterglow" of satisfying physical activity.

Immune modulation. β-Endorphin has documented anti-inflammatory and immunomodulatory effects. Immune cells express μ-opioid receptors, and locally produced β-endorphin can influence cytokine profiles, natural killer cell activity, and inflammatory tone.

Peripheral skin biology. Cutaneous β-endorphin production in response to UV light may partially explain the mood-elevating effects of sun exposure and has been implicated in the reinforcing (potentially addictive) quality of tanning behavior.

What Regulates Endorphin Production?

Understanding regulation is where clinical opportunity lives. Several systems influence how much β-endorphin your body produces and releases.

Neuroendocrine Drivers

The HPA axis is the primary neuroendocrine regulator of pituitary β-endorphin release. Corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP) from the hypothalamus stimulate POMC transcription and β-endorphin secretion from the anterior pituitary. This means that acute stress is a potent trigger for endorphin release—but chronic, unremitting HPA activation can dysregulate the system, potentially impairing POMC processing and leading to blunted endorphin responses over time.

Pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and catecholamines also drive POMC expression, particularly in immune cells. This creates a feedback loop where inflammation triggers local endorphin production, which in turn modulates the inflammatory response.

Environmental and Behavioral Modulators

Exercise. Physical activity is the most well-studied behavioral trigger for β-endorphin release. The evidence suggests that intensity and duration matter—moderate-to-vigorous exercise sustained for at least 20–30 minutes appears to be the threshold for meaningful β-endorphin elevation, though individual variation is significant.

Light exposure. UV radiation and specific wavelengths of blue light (around 453 nm) stimulate cutaneous POMC expression and β-endorphin release through a nitric-oxide-dependent mechanism. This is a peripheral pathway distinct from central endorphin production.

Stress patterns, sleep, and circadian alignment. Chronic sleep deprivation, circadian disruption, and unresolved psychological stress can all impair endorphin tone—likely through HPA axis dysregulation and downstream effects on POMC processing.

Clinical Levers: How to Support Healthy Endorphin Tone

From an integrative and functional medicine perspective, the goal is not to artificially spike endorphin levels (that is what exogenous opioids do, with well-known consequences), but rather to support the body's own endorphin-producing systems. Here are the evidence-informed strategies I consider in clinical practice.

1. Exercise (With an Important Caveat)

Exercise is the most reliable behavioral trigger for β-endorphin release, and moderate-to-vigorous activity sustained for roughly 20–30 minutes reliably raises circulating β-endorphin. For many clients managing chronic pain or low mood, regular movement is one of the most valuable tools available.

It is worth being precise about the mechanism, though, because the popular story oversimplifies it. The classic "runner's high" was long attributed to endorphins, but β-endorphin released into the bloodstream is a large, water-soluble molecule that does not readily cross the blood-brain barrier. Current evidence attributes much of the central euphoria and anxiety relief of the runner's high to endocannabinoids (such as anandamide), which are fat-soluble and do cross into the brain. So exercise-induced β-endorphin appears to act primarily in the periphery—modulating pain at sensory nerves, immune cells, and inflamed tissue—rather than producing the central "high" directly. This does not diminish exercise as a clinical lever; it simply means its benefits work through several overlapping systems, endorphins being one.

The type of exercise matters less than intensity, duration, and consistency, though activities that combine movement with social engagement (group fitness, partner workouts, dance) may offer additive benefits through the social-bonding dimension of endorphin signaling. One critical exception—patients with post-exertional malaise—is addressed in its own section below, because for them the standard exercise advice is not just unhelpful but potentially harmful.

2. Light and Skin POMC Activation

The discovery that skin keratinocytes produce β-endorphin in response to UV and blue-light exposure opens an interesting clinical avenue. Controlled, low-dose blue-light protocols (around 453 nm) may offer a way to stimulate cutaneous endorphin production without the skin cancer risk associated with uncontrolled UV exposure. This area is still emerging, and I approach it with appropriate caution, but it represents a promising intersection of photobiology and pain/mood management.

For clients who spend most of their time indoors, even ensuring adequate natural daylight exposure may support baseline endorphin tone through this peripheral pathway—alongside the well-established benefits for circadian rhythm and vitamin D synthesis.

3. Nutritional and Botanical Cofactors

Several nutritional strategies can support the biochemical machinery of endorphin production:

Amino acid adequacy. Because β-endorphin is a peptide, its production requires a sufficient pool of amino acids—particularly those forming the opioid-active N-terminal sequence. Adequate dietary protein intake is foundational.

B-vitamin support. Vitamins B6, folate, and B12 serve as cofactors in amino acid metabolism and one-carbon pathways that support peptide synthesis broadly.

Curcumin and capsaicin. Both compounds have been shown to enhance peripheral β-endorphin release. Capsaicin activates TRPV1 receptors, which triggers local endorphin release in sensory nerve terminals—this is part of the mechanism behind the paradoxical pain relief that follows the initial burn of capsaicin application. Curcumin appears to modulate opioid signaling through multiple pathways, including enhanced β-endorphin release and indirect μ-opioid receptor effects.

4. HPA Axis and Stress Optimization

Because the HPA axis is the master regulator of pituitary β-endorphin release, anything that restores healthy HPA function supports endorphin tone. In practice, this means prioritizing sleep quality, circadian regularity, and trauma-informed stress reduction strategies. The goal is to preserve the acute stress response (which triggers appropriate endorphin release) while avoiding the chronic HPA overdrive that can blunt the system over time.

This is where the integrative approach really shines—addressing the upstream drivers of HPA dysregulation (chronic inflammation, gut dysbiosis, mold/mycotoxin exposure, unresolved psychological trauma) rather than simply chasing the downstream symptom of low endorphin tone.

When Exercise Isn't an Option: Post-Exertional Malaise

Everything I've said about exercise comes with a significant exception, and it's one I take seriously in my practice. A meaningful subset of my clients—those living with ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome), Long COVID, and some presentations of fibromyalgia and dysautonomia—experience post-exertional malaise (PEM): a disproportionate, often delayed worsening of symptoms after physical, cognitive, or emotional exertion that can last days or weeks. For these individuals, the standard "just exercise more" advice is not merely unhelpful; it can trigger a crash and set recovery back.

This is why graded exercise therapy is no longer recommended as a treatment for ME/CFS—updated clinical guidance reversed the earlier position after evidence and patient reports showed it could cause harm in people with PEM. If you have PEM, the foundational principle is pacing: staying within your "energy envelope" and avoiding the boom-and-bust cycle that provokes crashes. Endorphin support, for you, has to come from levers that don't demand exertion.

Here are the approaches I consider for supporting endorphin tone without triggering PEM:

Light exposure. The skin's β-endorphin pathway is entirely non-exertional. Adequate daylight exposure—or controlled blue-light protocols where appropriate—can stimulate cutaneous β-endorphin production without any physical demand on the body. This is one of the few "endorphin levers" that costs virtually no energy.

Social connection, laughter, and music. These engage the central endorphin and opioid systems tied to social bonding and reward, and they can be accessed while resting. Shared laughter and music listening have both been associated with raised pain thresholds. For someone confined to bed or the home, connection and music are genuinely therapeutic, not just pleasant.

Gentle warmth. Warm baths or heat can be soothing and may support endorphin release—but this one requires individualization. Many people with ME/CFS, Long COVID, or POTS have heat intolerance or orthostatic issues, so warmth should be approached cautiously and abandoned if it worsens symptoms.

Acupuncture. Acupuncture is thought to work partly through stimulation of endogenous opioid (including β-endorphin) release, and it places minimal exertional demand on the client. In my practice, my medical acupuncture training makes this a natural option to consider for pain and stress modulation in energy-limited patients.

Peripheral nutritional support. Curcumin and adequate amino acid/B-vitamin status support the biochemical machinery of endorphin production without requiring activity.

Low Dose Naltrexone (LDN): A Particularly Relevant Tool

For clients with PEM, LDN deserves special mention—and it's an area of particular focus in my practice. LDN is naltrexone used at very low doses (typically starting around 0.5–1.5 mg and titrated slowly). One of its proposed mechanisms is directly relevant to this discussion: a brief, partial blockade of opioid receptors that the body responds to with a compensatory rebound increase in endogenous endorphin production and receptor sensitivity. In effect, it may nudge the endorphin system to upregulate itself—without any exertion required.

LDN has a second, likely more important mechanism as well: at low doses it appears to modulate glial cells in the central nervous system and reduce neuroinflammation, an effect thought to be largely independent of its opioid-receptor activity. This dual action is why LDN has drawn interest across exactly the conditions where PEM appears—ME/CFS, Long COVID, fibromyalgia, MCAS, and chronic pain. The clinical evidence base is still developing and much of the use is off-label, but the mechanism is biologically coherent, the safety profile is favorable, and for many energy-limited clients it offers a way to support endorphin and neuroimmune function that asks nothing of their limited physical reserves.

LDN requires a prescription and clinical supervision, including a slow titration and attention to timing and formulation. If you have PEM and are curious whether LDN fits your situation, this is a conversation worth having with a knowledgeable clinician.

A Note on Peptide Therapies and "Bioregulators"

The peptide therapy space has generated considerable interest in synthetic opioid peptide analogs (such as dermorphin and endomorphin analogs) and so-called bioregulators (short peptides marketed as tissue-specific regulators). It is important to be transparent about the current state of the evidence:

Synthetic opioid peptides remain in preclinical or early translational stages. No opioid peptide drug has been approved for clinical use as a CNS analgesic or mood agent. Research into enkephalinase inhibitors (compounds like opiorphin and spinorphin that prevent the breakdown of endogenous opioid peptides) is conceptually promising but has not yet produced approved therapeutics.

Khavinson-type bioregulators (Epithalamin/Epitalon, Cortexin, and similar compounds) are marketed for effects on HPA balance and stress resilience, but the evidence base is limited, largely preclinical, and not specific to endorphin pathways. I mention them here for completeness, not as a clinical recommendation.

The regulatory and safety landscape for exogenous opioid peptides is also important to consider. Any compound with significant μ-opioid receptor agonism carries inherent risks of tolerance, dependence, and respiratory depression. This is precisely why the clinical strategies outlined above—exercise, light, nutrition, and stress optimization—are preferred: they support endogenous production within the body's own regulatory safeguards rather than bypassing them.

The Bottom Line

Endorphins are far more than a feel-good chemical curiosity. They are central players in your body's pain management, stress response, immune regulation, and emotional well-being systems. The biochemistry of endorphin production—rooted in the POMC pathway—is elegantly complex but also responsive to practical, lifestyle-level interventions.

From an integrative medicine standpoint, optimizing endorphin tone means supporting the entire system: adequate nutrition and amino acid availability, regular moderate-to-vigorous exercise, healthy light exposure, circadian alignment, and HPA axis balance. These strategies work with the body's own regulatory architecture rather than against it—and they offer benefits that extend well beyond endorphin signaling alone.

If you are living with chronic pain, mood disorders, or stress-related conditions and want to explore how these strategies might apply to your specific situation, I encourage you to reach out.

References

1. Sprouse-Blum AS, Smith G, Sugai D, Parsa FD. Understanding endorphins and their importance in pain management. Hawaii Med J. 2010;69(3):70–71. PMID: 20397507.
2. Chaudhry SR, Rahimi N. Biochemistry, Endorphin. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2025. Bookshelf ID: NBK470306. PMID: 29262177.
3. Pilozzi A, Carro C, Huang X. Roles of β-endorphin in stress, behavior, neuroinflammation, and brain energy metabolism. Int J Mol Sci. 2020;22(1):338. PMID: 33396962.
4. Albers I, Zernickel E, Stern M, et al. Blue light (λ=453 nm) nitric oxide dependently induces β-endorphin production of human skin keratinocytes in-vitro and increases systemic β-endorphin levels in humans in-vivo. Free Radic Biol Med. 2019;145:78–86. PMID: 31553937.
5. Ghosh A, Chandra R, Jain U, Chauhan N. Investigating beta-endorphins: ways to boost health, conventional and future detection methods. Process Biochem. 2024;141:102–111. doi:10.1016/j.procbio.2024.03.009.
6. Fuss J, Steinle J, Bindila L, et al. A runner's high depends on cannabinoid receptors in mice. Proc Natl Acad Sci U S A. 2015;112(42):13105–13108. PMID: 26438875.
7. Siebers M, Biedermann SV, Fuss J. Do endocannabinoids cause the runner's high? Evidence and open questions. Neuroscientist. 2023;29(3):352–369. doi:10.1177/10738584211069981.
8. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459. PMID: 24526250.
9. Cabanas H, Muraki K, Eaton-Fitch N, Staines DR, Marshall-Gradisnik S. Potential therapeutic benefit of low dose naltrexone in myalgic encephalomyelitis/chronic fatigue syndrome: role of transient receptor potential melastatin 3 ion channels in pathophysiology and treatment. Front Immunol. 2021;12:687806. PMID: 34326841.

About Dr. Kim

Yoon Hang Kim, MD, MPH, is board-certified in Preventive Medicine and is an Integrative & Functional Medicine physician with over 20 years of clinical experience. He completed his fellowship at the University of Arizona's Andrew Weil Center for Integrative Medicine and holds certifications in preventive medicine, medical acupuncture, and integrative and holistic medicine. Dr. Kim specializes in low dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold toxicity. He is the author of 3 books and over 20 published articles.

Learn more at www.yoonhangkim.com | www.directintegrativecare.com